Arcus Biosciences, Inc. (RCUS)
USD 15.17
(-5.66%)
USD 15.17
(-5.66%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -306 Million | 438 Million | -256.17 Million | 111.17 Million | -73.46 Million | -42.99 Million |
| Net Income | -307 Million | -267 Million | 52.83 Million | -122.85 Million | -84.71 Million | -49.59 Million |
| Depreciation & Amortization | 8 Million | 6 Million | 3.84 Million | 4.19 Million | 3.57 Million | 3.66 Million |
| Deferred income taxes | -19 Million | - | 4.77 Million | - | - | -2.09 Million |
| Stock-based compensation | 73 Million | 65 Million | 55 Million | 22 Million | 8.98 Million | 3.87 Million |
| Change in working capital | -71 Million | 623 Million | -375.61 Million | 208.05 Million | 125 Thousand | 1.33 Million |
| Other non-cash items | 10 Million | 11 Million | 3.47 Million | -46 Thousand | -1.43 Million | -177 Thousand |
| Investing Cash Flow | 194 Million | -413 Million | -3.86 Million | -434.36 Million | 59.21 Million | -113.44 Million |
| Investments in PPE | -24 Million | -12 Million | -26.07 Million | -3.05 Million | -1.92 Million | -3.74 Million |
| Acquisitions | -218 Million | - | -22 Million | 431 Million | -61.13 Million | - |
| Investment purchases | -788 Million | -1.24 Billion | -718.86 Million | -739.65 Million | -247.75 Million | -261.55 Million |
| Sales/Maturities of investments | 1 Billion | 837 Million | 741.07 Million | 308.34 Million | 308.89 Million | 151.85 Million |
| Other Investing Activities | 218 Million | 3 Million | 22 Million | -431 Million | 61.13 Million | -109.69 Million |
| Financing Cash Flow | 33 Million | 33 Million | 237.34 Million | 438.67 Million | 1.12 Million | 129.07 Million |
| Debt repayment | - | -10 Million | -5 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -6000.00 | -54 Thousand | -94 Thousand | - |
| Common Stock Issuance | 33 Million | 23 Million | 220.23 Million | 433.77 Million | 1.21 Million | 125.11 Million |
| Other Financing Activities | 8 Million | 33 Million | 27.11 Million | 4.95 Million | 1.21 Million | 3.96 Million |
| Accounts receivables | 15 Million | 704 Million | -17.04 Million | -917 Thousand | -132 Thousand | -58 Thousand |
| Accounts payables | -1 Million | 8 Million | -4.77 Million | 9.27 Million | 1.72 Million | -69 Thousand |
| Inventory | -15 Million | -704 Million | 14.08 Million | 21.32 Million | 1.06 Million | - |
| Other working capital | -70 Million | 615 Million | -367.88 Million | 178.37 Million | -2.53 Million | 1.4 Million |
| Cash at beginning of period | 209 Million | 151 Million | 173.61 Million | 58.14 Million | 71.26 Million | 98.42 Million |
| Cash at end of period | 130 Million | 209 Million | 150.91 Million | 173.61 Million | 58.14 Million | 71.06 Million |
| Capital Expenditure | -24 Million | -12 Million | -26.07 Million | -3.05 Million | -1.92 Million | -3.74 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -79 Million | 58 Million | -22.69 Million | 115.47 Million | -13.12 Million | -27.36 Million |
| Free Cash Flow | -330 Million | 426 Million | -282.24 Million | 108.11 Million | -75.38 Million | -46.73 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -93 Million | -4 Million | -307 Million | -81 Million | -71 Million | -75 Million |
| Depreciation & Amortization | 2 Million | 3 Million | 8 Million | 3 Million | 1 Million | 2 Million |
| Deferred income taxes | - | - | -19 Million | 16 Million | -29 Million | 13 Million |
| Stock-based compensation | 20 Million | 20 Million | 73 Million | 18 Million | 18 Million | 18 Million |
| Change in working capital | -19 Million | -37 Million | -71 Million | -24 Million | -9 Million | -13 Million |
| Other non-cash items | 13 Million | 2 Million | 10 Million | -20 Million | 27 Million | -2 Million |
| Investing Cash Flow | 63 Million | -169 Million | 194 Million | 28 Million | 11 Million | 26 Million |
| Investments in PPE | - | -4 Million | -24 Million | -6 Million | -10 Million | -5 Million |
| Acquisitions | - | - | -218 Million | 21 Million | -21 Million | -31 Million |
| Investment purchases | -206 Million | -387 Million | -788 Million | -115 Million | -280 Million | -239 Million |
| Sales/Maturities of investments | 269 Million | 222 Million | 1 Billion | 149 Million | 301 Million | 270 Million |
| Other Investing Activities | 63 Million | -165 Million | 218 Million | -21 Million | 21 Million | 31 Million |
| Financing Cash Flow | 2 Million | 229 Million | 33 Million | 3 Million | 6 Million | 23 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -1 Million | - | - | - | - | - |
| Common Stock Issuance | 3 Million | 228 Million | 33 Million | 3 Million | 10 Million | 19 Million |
| Other Financing Activities | -1 Million | 1 Million | 8 Million | 8 Million | -4 Million | 4 Million |
| Accounts receivables | 7 Million | 13 Million | 15 Million | -11 Million | 11 Million | -2 Million |
| Accounts payables | - | -1 Million | -1 Million | 2 Million | 6 Million | -19 Million |
| Inventory | - | - | -15 Million | -6 Million | 6 Million | -11 Million |
| Other working capital | -26 Million | -42 Million | -70 Million | -9 Million | -32 Million | 19 Million |
| Cash at beginning of period | 185 Million | 130 Million | 209 Million | 187 Million | 233 Million | 241 Million |
| Cash at end of period | 156 Million | 188 Million | 130 Million | 130 Million | 187 Million | 233 Million |
| Capital Expenditure | - | -4 Million | -24 Million | -6 Million | -10 Million | -5 Million |
| Effect of forex changes on cash | - | - | - | -26 Million | - | 26 Million |
| Net cash flow / Change in cash | -29 Million | 58 Million | -79 Million | -57 Million | -46 Million | -8 Million |
| Free Cash Flow | -94 Million | -6 Million | -330 Million | -94 Million | -73 Million | -62 Million |
FFXXF
0RT6
4806
EBEN
RERE
CCL